Enhanced synaptic release of excitatory amino acid neurotransmitters may contribute to brain injury from hypoxia-ischemia (Meldrum, 1985; Simon et al., 1984) . To examine this hypothesis in neonatal brain we tested MK-80I, a novel noncompetitive N-methyl-D-aspartate (NMDA) receptor antagonist, using an in vivo experimental model of hypoxic-ischemic forebrain injury (Johnston, 1983) . To induce injury, seven day old rats were anesthetized with ether and the right carotid was ligated (N = 63), after which they recovered with the dam for 2 h. The pups were then placed in a warmed (37°C) chamber and exposed to 8% oxygen balance nitrogen for 3 h, a procedure which resulted in hemispheric necrosis ipsilateral to the side of ligation.
Effect of treatment was assessed using three MK-801 treatment protocols: administration of 1 dose of MK-801 (1 mg/kg) before hypoxia (N = 10), a single dose during hypoxia (N = 18), or two doses, one before and another after 1.25 h of hypoxia (N = 9). In the second group, the timing of treatment was varied to determine if there was a critical time threshold for efficacy: a single dose was given after 1.25 h (N = 5), 1.5 h (N = 6) or 2.5 h (N = 7). Pups received one or two intraperitoneal injections of MK = 801 (N = 37) or phosphate buffered saline (N = 26); a group of untreated litter-mates served as additional controls (N = 5). Pups were sacrificed 5 days after There was prominent neuronal loss in hippocampus, cortex and caudate-putamen of salinetreated ligates. MK-801 administration reduced hypoxic-ischemic neuronal damage both grossly and microscopically as compared the opposite side. When compared to saline treated hypoxic-ischemic controls, two MK-801 injections were most effective in reducing cerebral hemisphere damage (saline treated, -11.2 + 2 vs. -1.7 _+ 1.3% P < 0.001). Figure 1 compared littermate pups treated with saline or MK-801 at the onset and 1.25 h into hypoxia, to normal controls. A single MK-801 dose at the onset (-3.7 _+ 6.9 P < 0.05) or after 1.25 h of hypoxia (-3.1 _+ 3.2% P < 0.01) was similarly effective while single injections at 1.5 or 2.5 h into hypoxia were least effective. MK-801 eliminated moderate to severe injury (> 10% reduction in hemisphere weight) in protocols with two doses or a single dose at 1.25 h. The incidence of hemispheric necrosis in groups given a pre-hypoxia dose or treated at 1.5 h with MK-801 was reduced to 20 and 33%, respectively. The incidence of severe necrosis in pups that received MK-801 after 2.5 h of hypoxia (57%) was no different from saline treated controls. Thus, protocols in which MK-801 was administered before 1.25 h into hypoxia were most effective in limiting neuronal damage. The data suggest that there is a 0014-2999 /87/$03.50 © 1987 
